May 17th 8:00 AM - 12:00 PM

Location: iBio first floor conference room 6135 Woodward Avenue, Detroit, MI 48202

RSVP by May 12th here: https://waynestate.az1.qualtrics.com/jfe/form/SV_1BKs1i9TgtFYJ4a

Breakfast will be provided.

Please park in Lot 14 (6241 Cass Ave, Detroit, MI 48202) on Cass Ave, between Amsterdam and W Baltimore Ave. It is $12 for the day. If you're taking the Q line, get off on the Amsterdam (10) exit.

Talks will include subjects such as: Vaccine Acceptance in HIV+ Youth, Is air pollution an environmental risk for pediatric neurological syndromes in Detroit?, Clinical Characteristics of Children with Diabetic Ketoacidosis in the Pediatric Intensive Care Unit Before and During the COVID-19 Pandemic, Barriers to Epinephrine Auto-injector Use, and much more!

Learning Objectives: • Discuss ongoing research and recent developments in clinical, basic and translational research in pediatrics at Wayne State University and affiliates; • Provide a forum for collaboration and development of ideas related to pediatric research; • Discuss potential changes in practice that can be implemented based on presented research

Commercial Relationship Disclosure: No commercial disclosures to report.

The Wayne State University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.The Wayne State University School of Medicine designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit
(s) TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience: This activity is designed for physicians and other healthcare professionals interested in clinical, basic and translational research in pediatrics.
Department of Pediatrics Website Address: http://peds.med.wayne.edu/ For additional information contact: Jenn Brandt at:(313) 577-3231, or email: gt5824@wayne.edu

Committee members have the following financial disclosures: Tej K. Mattoo, MD, discloses that in the previous 24 months, he has been a consultant and speaker for ALNYLAM Pharmaceuticals. Eric McGrath, MD, discloses clinical research protocol with Gilead Sciences, Pfizer, ViiV, and Abbott/iProcess. Elizabeth Secord, MD, discloses clinical trials with Novavax, Pfizer, Abbott, and ViiV. Alan Dombkowski, PhD, discloses research funding from Mallinckrodt Pharmaceuticals, Y. Ravindrath, MD, discloses serving on the data monitoring committee for Agios Pharmaceuticals. Laura Benjamins, MD, has no financial disclosures. Any commercial relationships with ineligible companies as defined by the ACCME have been mitigated.